TY - JOUR
T1 - New developments in the medical management of prostate cancer
AU - Kohli, Manish
AU - Tindall, Donald J.
N1 - Funding Information:
This work was funded, in part, by National Cancer Institute Grant No. CA091956.
PY - 2010/1
Y1 - 2010/1
N2 - Prostate cancer is a substantial public health burden and a leading cause of cancer-related morbidity and mortality in the United States despite the observation that annual prostate cancer-specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.
AB - Prostate cancer is a substantial public health burden and a leading cause of cancer-related morbidity and mortality in the United States despite the observation that annual prostate cancer-specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=73649094457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73649094457&partnerID=8YFLogxK
U2 - 10.4065/mcp.2009.0442
DO - 10.4065/mcp.2009.0442
M3 - Review article
C2 - 20042563
AN - SCOPUS:73649094457
SN - 0025-6196
VL - 85
SP - 77
EP - 86
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 1
ER -